SPOTLIGHT: Ellence knockoff OK'd


Indian generics maker Dabur Pharma got the FDA's nod for its version of the Pfizer breast-cancer treatment Ellence, a $60 million-per-year drug in the U.S. It's Dabur's third FDA approval in twelve months. Report